Brain-eating amoebae can cause particularly harmful forms of encephalitis, and more than 95% of people who develop these rare but devastating infections die. Despite the high mortality rate, there is currently no single effective drug available to fight these microbes. Now, however, researchers have designed some new compounds that show promise in the laboratory as treatments, according to a report in ACS Chemical Neuroscience.
Naegleria fowleri and Balamuthia mandrillaris are two types of amoebae that can cause primary amoebic meningoencephalitis and granulomatous amoebic encephalitis. They are single-celled microorganisms that live in water and soil, and can enter the body through the nose or open wounds. These pathogens can then move to the central nervous system, where they destroy brain cells. In the very few cases that have been treated successfully, patients were given high doses of many different antimicrobials. However, these drugs generally lack specificity and can have toxic effects at high levels. To make progress toward a single drug, Ruqaiyyah Siddiqui and colleagues turned to quinazolinones. These compounds are effective against a wide spectrum of human foes, including bacteria, viruses, fungi, parasites and cancer, but they had never been tested against brain-eating amoebae.
The researchers synthesized 34 new quinazolinone derivatives and studied their effects on N. fowleri and B. mandrillaris. Some of the new compounds were effective at killing the microorganisms and limiting the harm the pathogens could do to human cells in a Petri dish. In some cases, attaching silver nanoparticles to the derivatives enhanced that activity. The most effective compounds contained chlorine, methyl or methoxy groups, and their toxicity for human cells was low. The researchers say their results show that quinazolinones are good candidates for drug development studies.
The authors acknowledge funding from the American University of Sharjah in the United Arab Emirates and the Husein Ebrahim Jamal Research Institute of Chemistry in Pakistan.
The abstract that accompanies this study is available here.
For more research news, journalists and public information officers are encouraged to apply for complimentary press registration for the ACS Spring 2020 National Meeting & Exposition in Philadelphia.
The American Chemical Society (ACS) is a nonprofit organization chartered by the U.S. Congress. ACS' mission is to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and its people. The Society is a global leader in providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, eBooks and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a specialist in scientific information solutions (including SciFinder® and STN®), its CAS division powers global research, discovery and innovation. ACS' main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive news releases from the American Chemical Society, contact email@example.com.